Comparative Mortality in Heart Failure on Guideline‐Directed Medical Therapy Versus Malignant Cancer: A Report From a Global Federated Research Network
Journal of the American Heart Association · 07.10.2025 · 14 (19)
DOI: 10.1161/jaha.125.044046 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 07.10.2025. Verfasst von Luca Monzo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre d'Investigations Cliniques Plurithématique 1433, INSERM U1116 - DCAC, CHRU de Nancy and F-CRIN INI-CRCT Université de Lorraine Nancy France. Hauptthemen laut MEDLINE: Neoplasms, Heart Failure, Practice Guidelines as Topic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Guideline‐directed medical therapy (GDMT), including angiotensin receptor‐neprilysin inhibitor, angiotensin‐converting enzyme inhibitors, beta blockers, mineralocorticoid receptor antagonists, and sodium‐glucose cotransporter‐2 inhibitors, has significantly improved outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We examined whether modern GDMT alters the historically observed parity in mortality between HF and cancer.
Methods
From the TriNetX Global Collaborative Research Network (2015–2024), we identified 32 125 patients with HFrEF on GDMT (angiotensin receptor‐neprilysin inhibitor or angiotensin‐converting enzyme inhibitors, mineralocorticoid receptor antagonists, beta blockers, and sodium‐glucose cotransporter‐2 inhibitors), 403 389 not on full GDMT (not receiving all 4 drugs concurrently), and 2 481 106 with malignant cancers. All‐cause mortality was compared between HFrEF and cancer overall and across the most common cancers in men (prostate, colorectal, lung) and women (breast, lung, colorectal) using propensity score matching.
Results
Patients with HFrEF on GDMT with angiotensin receptor‐neprilysin inhibitors had significantly better survival than patients with cancer (hazard ratio [HR], 0.44 [95% CI, 0.41–0.47]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre d'Investigations Cliniques Plurithématique 1433, INSERM U1116 - DCAC, CHRU de Nancy and F-CRIN INI-CRCT Université de Lorraine Nancy France.
- TriNetX Europe NV St. Martens-Latem Belgium.
- Division of Cardiology, Department of Medicine Karolinska Institutet Stockholm Sweden.
- Department of Clinical Science and Education Södersjukhuset; Karolinska Institutet Stockholm Sweden.
ORCID-Profile: Luca Monzo, Guillaume Baudry, Kevin Duarte, Gema Hernandez, Gianluigi Savarese, Nicolas Girerd
Zitieren
APA
Monzo, L., Baudry, G., Duarte, K., Hernandez, G., Denquin, O., Savarese, G., & Girerd, N. (2025). Comparative Mortality in Heart Failure on Guideline‐Directed Medical Therapy Versus Malignant Cancer: A Report From a Global Federated Research Network. Journal of the American Heart Association, 14(19). https://doi.org/10.1161/jaha.125.044046
Vancouver
Monzo L, Baudry G, Duarte K, Hernandez G, Denquin O, Savarese G, et al. Comparative Mortality in Heart Failure on Guideline‐Directed Medical Therapy Versus Malignant Cancer: A Report From a Global Federated Research Network. Journal of the American Heart Association. 2025;14(19). doi:10.1161/jaha.125.044046
BibTeX
@article{Monzo2025,
author = {Monzo, Luca and Baudry, Guillaume and Duarte, Kevin and Hernandez, Gema and Denquin, Olivier and Savarese, Gianluigi and Girerd, Nicolas},
title = {Comparative Mortality in Heart Failure on Guideline‐Directed Medical Therapy Versus Malignant Cancer: A Report From a Global Federated Research Network},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {19},
doi = {10.1161/jaha.125.044046}
}
EUVIMED